Last €2.48 EUR
Change Today -0.05 / -1.98%
Volume 10.3K
ALINS On Other Exchanges
Symbol
Exchange
EN Paris
As of 4:42 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

intrasense sas (ALINS) Snapshot

Open
€2.50
Previous Close
€2.53
Day High
€2.52
Day Low
€2.46
52 Week High
12/4/13 - €6.48
52 Week Low
10/1/14 - €2.46
Market Cap
10.5M
Average Volume 10 Days
8.2K
EPS TTM
--
Shares Outstanding
4.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTRASENSE SAS (ALINS)

Related News

No related news articles were found.

intrasense sas (ALINS) Related Businessweek News

No Related Businessweek News Found

intrasense sas (ALINS) Details

Intrasense SAS develops and markets Myrian, a multimodality software platform for the review and analysis of medical images in 3D and 4D to improve diagnostic accuracy, enhance patient management, monitor pathologies, and assess imaging endpoints for clinical trials. It offers Myrian Expert VL, a multimodality station for 3D post-processing and volumetric analysis; Myrian Expert, a visualization and 3D post-processing solution; Myrian Advance, a solution for 2D post-processing; and Myrian Pro, a multimodality station for 2D visualization. The company also provides guarantee, maintenance, installation, integration, and deployment services. It sells its products through a distribution network in France, Brazil, Russia, India, and China. The company was founded in 2004 and is based in Montpellier, France.

57 Employees
Last Reported Date: 04/29/14
Founded in 2004

intrasense sas (ALINS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

intrasense sas (ALINS) Key Developments

Erasmus University Medical Center Selects Intrasense's Myrian(R) for its Pulmonology Core Lab

Intrasense announced an agreement with LungAnalysis, Erasmus Medical Center's core lab. Erasmus MC has been an Intrasense scientific partner in the field of lung pathologies for several years. With this agreement, it extends the use of Myrian(R) to new advanced research activities, including academic clinical research, industry-sponsored trials and even patient care. The advanced and unique capabilities of its clinical application Myrian(R) XP-Lung allows to measure specific imaging biomarkers. This collaboration validates Intrasense strategy and ability to take advanced technology from clinical research to routine radiology.

Intrasense Launches Myrian(R) XP-Femalepelvis for the Diagnosis and Follow-Up of Ovarian and Cervical Cancers

Intrasense announced the launch of its new module Myrian(R) XP-FemalePelvis for the visualization and the multiparametric analysis of female pelvis MR exams. Magnetic Resonance Imaging (MRI) is the modality recommended by the European Society of Urogenital Radiology (ESUR) for the diagnosis and follow-up of these two cancers. This modality provides a large amount of functional and morphological data that require specific reading and interpretation tools and workflows. Based on the recommendations from ESUR, Myrian(R) XP-FemalePelvis implements the concept of Structured Reading(TM) developed by Intrasense. The user is thus guided through the analysis of female pelvis MRI exams according to the guidelines provided by the scientific society. In addition to optimizing reading workflows and generating considerable timesaving, this increases the consistency of data analysis, facilitates comparison with prior exams or exams from other modalities and enhances diagnosis quality. Moreover, Myrian(R) XP-FemalePelvis automates the creation of powerful and comprehensive reports including key images and data for an optimized communication between healthcare professionals and with the patient herself.

RadCore Labs Selects Intrasense's Myrian Platform

Intrasense announced the signature of a master agreement with RadCore Labs. Imaging CROs specialize in quantitative medical image analysis in clinical trials for the pharmaceutical and biotech industries thus providing their customers with a reliable assessment of response to treatments. Through this master agreement, all RadCore Labs studies requiring advanced visualization and imaging biomarkers measurements will now be performed using the Myrian platform developed by Intrasense. Myrian has indeed been selected by the American CRO for its advanced multimodality functions dedicated to oncology as well as its broad clinical coverage in other therapeutic areas. Myrian's advanced 3D quantification tools and outstanding ergonomics have also been key decisive factors. Myrian is deployed on a server as a thin client application, thus allowing both local and remote readers to review and process images anytime and anywhere. Along with a seamless integration into the CRO's cloud PACS solution, this generates substantial productivity gains and higher flexibility. The streamlined image reading workflow results in better quality, reproducible assessments and higher customer satisfaction.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALINS:FP €2.48 EUR -0.05

ALINS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALINS.
View Industry Companies
 

Industry Analysis

ALINS

Industry Average

Valuation ALINS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTRASENSE SAS, please visit www.intrasense.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.